JMJD1C and leukemia: Loss of JMJD1C significantly reduces the LSC frequency in MLL-AF9 and HOXA9/MEIS1 leukemias.140 In this respect, some HDTs binding to oncogenic TFs have been suggested as drug targets (Fig. 5).